Chemotherapy and Radiation for Rectal Cancer
Author Information
Author(s): Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Marone P, Cascini L G, Morrica B, Lastoria S, Parisi V, Budillon A, Comella P
Primary Institution: National Tumour Institute, Naples, Italy
Hypothesis
The study evaluates the effectiveness of a chemotherapy combination during preoperative radiation therapy for locally advanced rectal cancer.
Conclusion
The combination of oxaliplatin, raltitrexed, and 5-fluorouracil with pelvic radiation therapy shows acceptable toxicity and high clinical activity in patients at high risk of recurrence.
Supporting Evidence
- 71% of patients achieved a tumor regression grade of 1 or 2.
- All patients are alive and recurrence-free after a median follow-up of 29 months.
- Severe toxicity was manageable, with no toxic deaths reported.
Takeaway
Doctors tested a new medicine mix to help people with a type of bowel cancer before surgery, and it worked well without causing too many problems.
Methodology
Patients received three biweekly courses of chemotherapy during pelvic radiation therapy, followed by surgery.
Limitations
The study was limited to patients at high risk of recurrence, which may not represent all rectal cancer patients.
Participant Demographics
The study included 51 patients with locally advanced rectal cancer, with a median age of 63 years.
Statistical Information
Confidence Interval
95% confidence limits, 52–86%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website